Header_Image_Investors
Corporate Profile

Theseus Pharmaceuticals is passionately committed to improving the lives of cancer patients by working to outsmart cancer resistance. Led by a team of targeted oncology pioneers with a proven track record developing and commercializing cancer therapeutics, the Company is developing next-generation tyrosine kinase inhibitors (TKIs): “pan-variant” targeted therapies that address all major drug resistant mutations. Theseus believes a pan-variant approach is the most effective way to address cancer resistance.

The Company’s lead program, THE-630, is a pan-variant KIT inhibitor for patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing THE-349: a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).

Corporate Presentation
Stock Price
NASDAQTHRX
Recent News Releases from Theseus
Nov 3, 2022

All sites open and actively enrolling in Phase 1 portion of Phase 1/2 clinical trial of THE-630 in advanced GIST; preliminary dose escalation data expected in Q2 2023 Preclinical data...

Oct 26, 2022

Potent single-molecule inhibition of all major classes of EGFR activating and resistance mutations, including C797X and T790M, with a high degree of kinome and wild-type EGFR selectivity Deep and...

Oct 19, 2022

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery,...

View All

Recent Events
Wednesday, September 14, 2022
3:30pm EDT
Tuesday, September 13, 2022
12:00pm EDT
Wednesday, August 10, 2022
10:20am EDT

View all